A Phase II, Multicenter, Single-Arm, Feasibility Study of Eribulin in Combination With Capecitabine for Adjuvant Treatment in Estrogen Receptor-Positive Early Stage Breast Cancer

Trial Profile

A Phase II, Multicenter, Single-Arm, Feasibility Study of Eribulin in Combination With Capecitabine for Adjuvant Treatment in Estrogen Receptor-Positive Early Stage Breast Cancer

Completed
Phase of Trial: Phase II

Latest Information Update: 22 Jun 2016

At a glance

  • Drugs Eribulin (Primary) ; Capecitabine
  • Indications Early breast cancer; Male breast cancer
  • Focus Pharmacokinetics
  • Sponsors Eisai Inc
  • Most Recent Events

    • 18 Dec 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
    • 12 Nov 2013 Planned End Date changed from 1 Nov 2012 to 1 May 2014 as reported by ClinicalTrials.gov.
    • 16 May 2013 Results will be presented at the Annual Meeting of the American Society of Clinical Oncology (ASCO-2013).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top